| HIV Infections
Biktarvy vs Truvada
Side-by-side clinical, coverage, and cost comparison for hiv infections.Deep comparison between: Biktarvy vs Truvada with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTruvada has a higher rate of injection site reactions vs Biktarvy based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Truvada but not Biktarvy, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Biktarvy
Truvada
At A Glance
Oral
Daily
INSTI + NRTI combination
Oral
Once daily
NRTI combination (FTC + TDF)
Indications
- HIV Infections
- HIV Infections
Dosing
HIV Infections - adults and pediatric >= 25 kg One tablet (50 mg BIC/200 mg FTC/25 mg TAF) taken orally once daily with or without food; on hemodialysis days, administer after hemodialysis completion.
HIV Infections - pediatric 14 kg to < 25 kg One tablet (30 mg BIC/120 mg FTC/15 mg TAF) taken orally once daily with or without food.
HIV Infections - virologically-suppressed pregnant individuals One tablet (50 mg BIC/200 mg FTC/25 mg TAF) taken orally once daily with or without food; monitor viral load closely due to lower drug exposures during pregnancy.
HIV Infections Adults and pediatric patients weighing >=35 kg: one tablet (200 mg FTC/300 mg TDF) once daily orally with or without food; pediatric patients weighing 17 to <35 kg: weight-based lower-strength tablet (100 mg/150 mg, 133 mg/200 mg, or 167 mg/250 mg) once daily; CrCl 30-49 mL/min: one tablet every 48 hours; CrCl <30 mL/min or hemodialysis: not recommended.
HIV-1 Pre-Exposure Prophylaxis HIV-1 uninfected adults and adolescents weighing >=35 kg: one tablet (200 mg FTC/300 mg TDF) once daily orally with or without food; not recommended if CrCl <60 mL/min.
Contraindications
- Co-administration with dofetilide due to potential for increased dofetilide plasma concentrations and serious or life-threatening events
- Co-administration with rifampin due to substantially decreased BIC plasma concentrations, which may result in loss of therapeutic effect and development of resistance
- Unknown or positive HIV-1 status when used for HIV-1 PrEP
Adverse Reactions
Most common (>=5%) Diarrhea, nausea, headache
Serious Severe acute exacerbations of hepatitis B, immune reconstitution syndrome, new onset or worsening renal impairment, lactic acidosis/severe hepatomegaly with steatosis
Postmarketing Acute renal failure, acute tubular necrosis, proximal renal tubulopathy, Fanconi syndrome, angioedema, Stevens-Johnson syndrome/toxic epidermal necrolysis, urticaria, weight increased
Most common (>=10%) Diarrhea, nausea, fatigue, headache, dizziness, depression, insomnia, abnormal dreams, rash
Serious Severe acute exacerbations of hepatitis B, new onset or worsening renal impairment, immune reconstitution syndrome, bone loss and mineralization defects, lactic acidosis/severe hepatomegaly with steatosis
Postmarketing Allergic reaction including angioedema, lactic acidosis, hypokalemia, hypophosphatemia, dyspnea, pancreatitis, hepatic steatosis, hepatitis, rash, rhabdomyolysis, osteomalacia, muscular weakness, myopathy, acute renal failure, Fanconi syndrome, proximal renal tubulopathy, interstitial nephritis, nephrogenic diabetes insipidus, proteinuria, asthenia
Pharmacology
BIKTARVY is a fixed-dose combination antiretroviral containing bictegravir (BIC), an integrase strand transfer inhibitor (INSTI) that blocks integration of HIV-1 DNA into host genomic DNA, plus emtricitabine (FTC) and tenofovir alafenamide (TAF), both nucleoside analog reverse transcriptase inhibitors (NRTIs) that terminate viral DNA chain elongation by competing with natural nucleoside substrates.
FTC and TDF are both nucleoside analog reverse transcriptase inhibitors (NRTIs); each is converted intracellularly to an active triphosphate form that inhibits HIV-1 reverse transcriptase by competing with natural dNTP substrates and causing chain termination. No antagonism between FTC and TDF has been observed in cell culture combination studies.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Biktarvy
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
Truvada
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Biktarvy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Truvada
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Biktarvy
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Truvada
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BiktarvyView full Biktarvy profile
TruvadaView full Truvada profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.